Pharmathene, Inc (PIP): Eric I Richman , director of Pharmathene, Inc sold 11,767 shares on Apr 7, 2016. The Insider selling transaction was disclosed on Apr 11, 2016 to the Securities and Exchange Commission. The shares were sold at $2.20 per share for a total value of $25,887.40.
Currently the company Insiders own 5.67% of PharmAthene shares according to the proxy statements.Institutional Investors own 42.43% of PharmAthene shares.
PharmAthene: On Monday, Apr 11, 2016 heightened volatility was witnessed in PharmAthene which led to swings in the share price. The shares opened for trading at $2.18 and hit $2.18 on the upside , eventually ending the session at $2.17, with a gain of 1.40% or 0.03 points. The heightened volatility saw the trading volume jump to 1,34,197 shares. The 52-week high of the share price is $2.2 and the company has a market cap of $142 M . The 52-week low of the share price is at $1.2.
Pharmathene Inc. (Pharmathene) is a biodefense company. The Company is engaged in the development of medical counter measures against biological and chemical threats. The Company has several biodefense candidates in its portfolio: Anthrax vaccines including SparVax which is a second generation liquid recombinant protective antigen (rPA) anthrax vaccine and a lyophilized anthrax vaccine containing rPA; rBChE (recombinant butyrylcholinesterase) bioscavenger which is a medical counter measure for nerve agent poisoning by organophosphorous (OP) compounds including nerve gases and pesticides and Valortim which is a fully human monoclonal antibody for the prevention and treatment of anthrax infection. The Company develops Valortim in collaboration with Bristol-Myers Squibb (BMS).